Karren R. Williams

The burden of familial chylomicronemia syndrome from the patients’ perspective

Alan S. Brown, A. Gelrud, A. Gwosdow, 2017, Expert review of cardiovascular therapy.

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

D. Gaudet, M. Arca, S. Tsimikas, 2019, The New England journal of medicine.

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

R. Santos, D. Blom, L. Hemphill, 2017, Journal of clinical lipidology.

Real-world evidence for a prescription digital therapeutic to treat opioid use disorder

Hilary F Luderer, R. Gerwien, Bruce Imbert, 2020, Current medical research and opinion.

Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS †

D. Gaudet, E. Bruckert, E. Stroes, 2018 .

Evaluating the impact of peer support and connection on the quality of life of patients with familial chylomicronemia syndrome

David B. Davidson, A. Gwosdow, A. Hsieh, 2018, Expert Opinion on Orphan Drugs.